277 related articles for article (PubMed ID: 25451136)
1. Formulation and stabilization of recombinant protein based virus-like particle vaccines.
Jain NK; Sahni N; Kumru OS; Joshi SB; Volkin DB; Russell Middaugh C
Adv Drug Deliv Rev; 2015 Oct; 93():42-55. PubMed ID: 25451136
[TBL] [Abstract][Full Text] [Related]
2. Antigen delivery by virus-like particles for immunotherapeutic vaccination.
Al-Barwani F; Donaldson B; Pelham SJ; Young SL; Ward VK
Ther Deliv; 2014 Nov; 5(11):1223-40. PubMed ID: 25491672
[TBL] [Abstract][Full Text] [Related]
3. Structural Characterization and Formulation Development of a Trivalent Equine Encephalitis Virus-Like Particle Vaccine Candidate.
Toprani VM; Cheng Y; Wahome N; Khasa H; Kueltzo LA; Schwartz RM; Middaugh CR; Joshi SB; Volkin DB
J Pharm Sci; 2018 Oct; 107(10):2544-2558. PubMed ID: 29883665
[TBL] [Abstract][Full Text] [Related]
4. Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine.
Mulder AM; Carragher B; Towne V; Meng Y; Wang Y; Dieter L; Potter CS; Washabaugh MW; Sitrin RD; Zhao Q
PLoS One; 2012; 7(4):e33235. PubMed ID: 22493667
[TBL] [Abstract][Full Text] [Related]
5. Formulation Studies During Preclinical Development of Influenza Hemagglutinin and Virus-Like Particle Vaccine Candidates.
Wahome N; Hickey JM; Volkin DB; Middaugh CR
Methods Mol Biol; 2016; 1404():393-421. PubMed ID: 27076313
[TBL] [Abstract][Full Text] [Related]
6. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies.
Kumru OS; Joshi SB; Smith DE; Middaugh CR; Prusik T; Volkin DB
Biologicals; 2014 Sep; 42(5):237-59. PubMed ID: 24996452
[TBL] [Abstract][Full Text] [Related]
7. Challenges and opportunities of using liquid chromatography and mass spectrometry methods to develop complex vaccine antigens as pharmaceutical dosage forms.
Hickey JM; Sahni N; Toth RT; Kumru OS; Joshi SB; Middaugh CR; Volkin DB
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():23-38. PubMed ID: 27071526
[TBL] [Abstract][Full Text] [Related]
8. Assessing sequence plasticity of a virus-like nanoparticle by evolution toward a versatile scaffold for vaccines and drug delivery.
Lu Y; Chan W; Ko BY; VanLang CC; Swartz JR
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12360-5. PubMed ID: 26392546
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant formulations for virus-like particle (VLP) based vaccines.
Cimica V; Galarza JM
Clin Immunol; 2017 Oct; 183():99-108. PubMed ID: 28780375
[TBL] [Abstract][Full Text] [Related]
10. Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination.
Mohsen MO; Gomes AC; Cabral-Miranda G; Krueger CC; Leoratti FM; Stein JV; Bachmann MF
J Control Release; 2017 Apr; 251():92-100. PubMed ID: 28257987
[TBL] [Abstract][Full Text] [Related]
11. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
[TBL] [Abstract][Full Text] [Related]
12. The 5th virus-like particle and nano-particle vaccines (VLPNPV) conference.
Engeroff P; Bachmann MF
Expert Rev Vaccines; 2019 Jan; 18(1):1-3. PubMed ID: 30526126
[TBL] [Abstract][Full Text] [Related]
13. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
14. Liposomal adjuvants: preparation and formulation with antigens.
Haensler J
Methods Mol Biol; 2010; 626():73-90. PubMed ID: 20099122
[TBL] [Abstract][Full Text] [Related]
15. Virus-like particle vaccines: immunology and formulation for clinical translation.
Donaldson B; Lateef Z; Walker GF; Young SL; Ward VK
Expert Rev Vaccines; 2018 Sep; 17(9):833-849. PubMed ID: 30173619
[TBL] [Abstract][Full Text] [Related]
16. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
[TBL] [Abstract][Full Text] [Related]
17. Vaccine technologies: From whole organisms to rationally designed protein assemblies.
Karch CP; Burkhard P
Biochem Pharmacol; 2016 Nov; 120():1-14. PubMed ID: 27157411
[TBL] [Abstract][Full Text] [Related]
18. Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine.
Chuan YP; Rivera-Hernandez T; Wibowo N; Connors NK; Wu Y; Hughes FK; Lua LH; Middelberg AP
Biotechnol Bioeng; 2013 Sep; 110(9):2343-51. PubMed ID: 23532896
[TBL] [Abstract][Full Text] [Related]
19. Enveloped virus-like particle platforms: vaccines of the future?
Pitoiset F; Vazquez T; Bellier B
Expert Rev Vaccines; 2015 Jul; 14(7):913-5. PubMed ID: 25968245
[TBL] [Abstract][Full Text] [Related]
20. Virus-like particle formulation optimization by miniaturized high-throughput screening.
Mohr J; Chuan YP; Wu Y; Lua LH; Middelberg AP
Methods; 2013 May; 60(3):248-56. PubMed ID: 23639868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
